Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial

Importance: The effects of loading doses of statins on clinical outcomes in patients with acute coronary syndrome (ACS) and planned invasive management remain uncertain.

Objective: To determine if periprocedural loading doses of atorvastatin decrease 30-day major adverse cardiovascular events (MACE) in patients with ACS and planned invasive management.

Design, Setting, And Participants: Multicenter, double-blind, placebo-controlled, randomized clinical trial conducted at 53 sites in Brazil among 4191 patients with ACS evaluated with coronary angiography to proceed with a percutaneous coronary intervention (PCI) if anatomically feasible. Enrollment occurred between April 18, 2012, and October 6, 2017. Final follow-up for 30-day outcomes was on November 6, 2017.

Interventions: Patients were randomized to receive 2 loading doses of 80 mg of atorvastatin (n = 2087) or matching placebo (n = 2104) before and 24 hours after a planned PCI. All patients received 40 mg of atorvastatin for 30 days starting 24 hours after the second dose of study medication.

Main Outcomes And Measures: The primary outcome was MACE, defined as a composite of all-cause mortality, myocardial infarction, stroke, and unplanned coronary revascularization through 30 days.

Results: Among the 4191 patients (mean age, 61.8 [SD, 11.5] years; 1085 women [25.9%]) enrolled, 4163 (99.3%) completed 30-day follow-up. A total of 2710 (64.7%) underwent PCI, 333 (8%) underwent coronary artery bypass graft surgery, and 1144 (27.3%) had exclusively medical management. At 30 days, 130 patients in the atorvastatin group (6.2%) and 149 in the placebo group (7.1%) had a MACE (absolute difference, 0.85% [95% CI, -0.70% to 2.41%]; hazard ratio, 0.88; 95% CI, 0.69-1.11; P = .27). No cases of hepatic failure were reported; 3 cases of rhabdomyolysis were reported in the placebo group (0.1%) and 0 in the atorvastatin group.

Conclusions And Relevance: Among patients with ACS and planned invasive management with PCI, periprocedural loading doses of atorvastatin did not reduce the rate of MACE at 30 days. These findings do not support the routine use of loading doses of atorvastatin among unselected patients with ACS and intended invasive management.

Trial Registration: clinicaltrials.gov Identifier: NCT01448642.

Citing Articles

Effect of perioperative remote ischemic conditioning on myocardial injury in patients with unstable angina undergoing percutaneous coronary intervention: protocol of a multicenter, randomized, double-blind clinical trial.

Xia L, Yang Q, Jiang L, Zheng Y, Chen L, Lin S Trials. 2025; 26(1):63.

PMID: 39984971 PMC: 11844111. DOI: 10.1186/s13063-025-08744-7.

The Serial Mediation Effects of Social Support and Self-Efficacy on Health Literacy and Self-Management Behaviors Among Young and Middle-Aged Cardiac Patients After Percutaneous Coronary Intervention: A Cross-Sectional Study in China.

Liu W, Qian S, Hu Y, Zhang R Risk Manag Healthc Policy. 2024; 17:2893-2906.

PMID: 39600348 PMC: 11590655. DOI: 10.2147/RMHP.S486800.

Commencement of Atorvastatin and Ezetimibe Immediately in Patients Presenting with Acute Coronary Syndrome.

Sallam M, Hassan H, Connolly D, Rahman M Eur Cardiol. 2024; 19:e22.

PMID: 39588251 PMC: 11588103. DOI: 10.15420/ecr.2024.06.

Association of serum cystatin C level and major adverse cardiovascular events in patients with percutaneous coronary intervention.

Xiao Z, Riletu A, Yan X, Meng Q, Zhang W, Zhang N Cardiovasc Diagn Ther. 2024; 14(4):621-629.

PMID: 39263480 PMC: 11384458. DOI: 10.21037/cdt-23-482.

Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease.

Yang C, Wu Y, Qian J, Li J Rev Cardiovasc Med. 2024; 24(12):373.

PMID: 39077097 PMC: 11272851. DOI: 10.31083/j.rcm2412373.

References

Kim J, Kim J, Choi D, Lee C, Lee S, Ko Y . Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010; 3(3):332-9. DOI: 10.1016/j.jcin.2009.11.021. View

Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-81. PMC: 2988224. DOI: 10.1016/S0140-6736(10)61350-5. View

Ridker P, Everett B, Thuren T, MacFadyen J, Chang W, Ballantyne C . Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12):1119-1131. DOI: 10.1056/NEJMoa1707914. View

Stone N, Robinson J, Lichtenstein A, Merz C, Blum C, Eckel R . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 63(25 Pt B):2889-934. DOI: 10.1016/j.jacc.2013.11.002. View

Lansky A, Stone G . Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv. 2010; 3(6):602-10. DOI: 10.1161/CIRCINTERVENTIONS.110.959080. View

Giugliano R, White J, Bode C, Armstrong P, Montalescot G, Lewis B . Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009; 360(21):2176-90. DOI: 10.1056/NEJMoa0901316. View

Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A . Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009; 54(23):2157-63. DOI: 10.1016/j.jacc.2009.07.005. View

Rosenson R, Tangney C . Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998; 279(20):1643-50. DOI: 10.1001/jama.279.20.1643. View

Winchester D, Wen X, Xie L, Bavry A . Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J Am Coll Cardiol. 2010; 56(14):1099-109. DOI: 10.1016/j.jacc.2010.04.023. View

10.

Cavallini C, Savonitto S, Violini R, Arraiz G, Plebani M, Olivari Z . Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J. 2005; 26(15):1494-8. DOI: 10.1093/eurheartj/ehi173. View

11.

Chaitman B, Thygesen K, Alpert J, White H, Jaffe A, Katus H . Third universal definition of myocardial infarction. Eur Heart J. 2012; 33(20):2551-67. DOI: 10.1093/eurheartj/ehs184. View

12.

Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G . Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007; 49(12):1272-8. DOI: 10.1016/j.jacc.2007.02.025. View

13.

Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G . Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004; 110(6):674-8. DOI: 10.1161/01.CIR.0000137828.06205.87. View

14.

Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A . Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol. 2009; 54(6):558-65. DOI: 10.1016/j.jacc.2009.05.028. View

15.

Berwanger O, de Barros E Silva P, Dall Orto F, de Andrade P, de Castro Bienert I, Bosso C . Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. Am Heart J. 2018; 198:129-134. DOI: 10.1016/j.ahj.2017.12.018. View

16.

Nohria A, Prsic A, Liu P, Okamoto R, Creager M, Selwyn A . Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis. 2009; 205(2):517-21. PMC: 2717178. DOI: 10.1016/j.atherosclerosis.2008.12.023. View

17.

Wang C, Liu P, Liao J . Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2007; 14(1):37-44. PMC: 2621332. DOI: 10.1016/j.molmed.2007.11.004. View

18.

OGara P, Ascheim D, Casey Jr D, Chung M, de Lemos J, Ettinger S . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012; 127(4):e362-425. DOI: 10.1161/CIR.0b013e3182742cf6. View

19.

Patti G, Cannon C, Murphy S, Mega S, Pasceri V, Briguori C . Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation. 2011; 123(15):1622-32. DOI: 10.1161/CIRCULATIONAHA.110.002451. View

20.

Amsterdam E, Wenger N, Brindis R, Casey Jr D, Ganiats T, Holmes Jr D . 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 64(24):e139-e228. DOI: 10.1016/j.jacc.2014.09.017. View